arrow
M

Marcelo V. Negrão

ut md anderson cancer center
H指数:35
被引数:5,838

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy

SUNRAY-02:奥莫罗西比与免疫疗法联合治疗经根治性治疗后处于II-III期KRAS G12C突变型非小细胞肺癌的研究

2026-10-010
OA
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC

SUNRAY-01试验方案:一项关于olomorasib和pembrolizumab联合或不联合化疗治疗KRAS G12C NSCLC的创新性研究设计

2026-04-060
PRE
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer

MET过表达与晚期非小细胞肺癌中更优的免疫治疗效果相关联

2025-11-270
OAAI
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report

达拉他单抗在未经治疗的SCLC脑转移患者中快速颅内应答——真实世界病例系列:病例报告

2025-03-240
PRE
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
2025-01-010
PRE
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

CTLA4阻断消除KEAP1/STK11-related对PD-(L)1抑制剂的抗性

Nature
IF48.5
2024-10-090
OAAI
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer

KRAS突变型非小细胞肺癌对RAS活性抑制的反应及耐受机制

2024-07-053
PRE
An atlas of epithelial cell states and plasticity in lung adenocarcinoma

肺腺癌上皮细胞状态和可塑性的图谱

Nature
IF48.5
2024-02-280
OAAI
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
2023-07-0410
OAAI
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
2023-07-0127
OAAI
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

KRASG12C抑制剂在晚期NSCLC中的疗效和作用

2023-04-1765
OA
A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas
2023-04-143
PRE